Anti-Phospho-RELB (S573) Antibody

Product Name

Anti-Phospho-RELB (S573) Antibody

View all RELB Antibodies

SKU/Catalog Number

P00836

Size

100 μl/vial

Form

Liquid

Description

Boster Bio Anti-Phospho-RELB (S573) Antibody catalog # P00836. Tested in WB, IHC, ICC, IF applications. This antibody reacts with Human, Mouse.

Storage & Handling

12 months from date of receipt，-20℃ as supplied. 6 months 2 to 8℃ after reconstitution. Avoid repeated freezing and thawing.

Cite This Product

Anti-Phospho-RELB (S573) Antibody (Boster Biological Technology, Pleasanton CA, USA, Catalog # P00836)

Host

Rabbit

Contents

500 μg/ml antibody with PBS, 0.02% NaN3, 1 mg stabilizing protein and 50% glycerol
This antibody is supplied in a stabilized formulation.
Compatibility with conjugation reactions depends on the chemistry of the conjugation method used.
For conjugation methods that are not compatible with the stabilizing components present in this formulation, a carrier-free antibody format is required.

Clonality

Polyclonal

Immunogen

A synthesized peptide derived from human RelB around the phosphorylation site of Ser573.

Reactive Species

P00836 is reactive to RELB in Human, Mouse

Calculated molecular weight

62.1 kDa

Background of RELB

RELB (v-rel reticuloendotheliosis viral oncogene homolog B) is also known as IREL. The International Radiation Hybrid Mapping Consortium assigned the RELB gene to chromosome 19. By RT-PCR and immunocytochemical analyses, Clark et al. (1999) showed that RELB expression correlated with dendritic cell activation. NF-kappa-B-inducing kinase is required for osteoclastogenesis in response to pathologic stimuli. Vaira et al. (2008) found that overexpression of Relb, but not Rela, rescued differentiation of mouse Nik -/- osteoclast precursors, indicating that blockade of the alternative NF-kappa-B pathway, rather than the classical NF-kappa-B pathway, is responsible for the osteoclastogenic defect in the absence of Nik. Using Relb -/- mice, they showed that Relb itself was required for Rankl-induced osteoclastogenesis in vitro and for TNF-induced bone resorption in vivo. Both Relb -/- and Nik -/- mice were resistant to tumor-mediated osteolysis. Vaira et al. (2008) concluded that the alternative NF-kappa-B pathway, via RELB, plays an essential and unique role in RANKL signaling toward osteoclast development.

Antibody Validation

Boster validates all antibodies on WB, IHC, ICC, Immunofluorescence, and ELISA with known positive control and negative samples to ensure specificity and high affinity, including thorough antibody incubations.

View more details

Applications

P00836 is guaranteed for IF, IHC, ICC, WB Boster Guarantee

Assay Dilutions Recommendation

The recommendations below provide a starting point for assay optimization. The actual working concentration varies and should be decided by the user.

Western blot, 1:500-2000
Immunohistochemistry, 1:50-200
Immunocytochemistry/Immunofluorescence, 1:50-200

Validation Images & Assay Conditions

There are currently no images for this product. We are working on uploading them please check back shortly or contact us to expedite our upload process for this antibody.

See full target information RELB

Here are featured tools and databases that you might find useful.

• Boster's Pathways Library
• Protein Databases
• Bioscience Research Protocol Resources
• Data Processing & Analysis Software
• Photo Editing Software
• Scientific Literature Resources
• Research Paper Management Tools
• Molecular Biology Software
• Primer Design Tools
• Bioinformatics Tools
• Phylogenetic Tree Analysis